
|Articles|August 15, 2004
Advances in cryptorchidism, VUR deliver key benefits
Dextranomer/hyaluronic acid has the potential to lower the cost and also the morbidity of repeated voiding cystourethrograms in children.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Cretostimogene Grenadenorepvec: Mechanism and Rationale
5












